Healthcare & Pharmaceuticals Services
Some of the sector’s challenges include a constitutional imperative which requires the realisation of everyone’s right of access to healthcare, a need to bridge sustainably the divide between public and private sectors, and an increasing myriad of regulation. Post-pandemic, a new healthcare landscape will emerge, with the recognition that health is a primary asset, an emphasis on lower cost and preventative solutions as well as digital health and precision medicine, innovation in impactful public/private partnerships, and the continued global vaccine race. Successfully competing in this sector requires creative strategies and integrated solutions.
Sector services offered:
- Healthcare policy work
- Regulatory assistance
- Commenting on draft industry regulations and legislation
- Pharmaceutical licensing and distribution arrangements
- Cannabis law
- Digital health, telemedicine and healthtech
- Pharmacy and hospital licensing applications and disputes
- Public private partnerships
- Healthcare financing and insurance
- Privacy and the protection of personal information
- Administrative and constitutional law issues
- Multidisciplinary practice assistance (competition law/anti-trust, employment law, BBBEE, dispute resolution, tax)
- Mergers and Acquisitions
- Pro bono and human rights
Healthcare & Pharmaceuticals Brochures
Services
Healthcare & Pharmaceuticals Services
Some of the sector’s challenges include a constitutional imperative which requires the realisation of everyone’s right of access to healthcare, a need to bridge sustainably the divide between public and private sectors, and an increasing myriad of regulation. Post-pandemic, a new healthcare landscape will emerge, with the recognition that health is a primary asset, an emphasis on lower cost and preventative solutions as well as digital health and precision medicine, innovation in impactful public/private partnerships, and the continued global vaccine race. Successfully competing in this sector requires creative strategies and integrated solutions.
Sector services offered:
- Healthcare policy work
- Regulatory assistance
- Commenting on draft industry regulations and legislation
- Pharmaceutical licensing and distribution arrangements
- Cannabis law
- Digital health, telemedicine and healthtech
- Pharmacy and hospital licensing applications and disputes
- Public private partnerships
- Healthcare financing and insurance
- Privacy and the protection of personal information
- Administrative and constitutional law issues
- Multidisciplinary practice assistance (competition law/anti-trust, employment law, BBBEE, dispute resolution, tax)
- Mergers and Acquisitions
- Pro bono and human rights
Brochures
Healthcare & Pharmaceuticals Brochures
Healthcare & Pharmaceuticals Lawyers
Our multidisciplinary team develops creative strategies and integrated solutions for this important healthcare sector.
Our Healthcare & Pharmaceuticals LawyersSECTOR HEAD
Healthcare & Pharmaceuticals News
More newsHealth practitioners scrubbing in as shareholders: Navigating HPCSA approval for investments
Owning shares in a hospital or healthcare institution (Healthcare Practice) may be enticing for health practitioners, but compliance with regulatory requirements is essential before concluding any acquisition.
Legal, clinical and commercial risk associated with GLP-1 drugs
Charles Green, Senior Associate in the Healthcare & Pharmaceuticals sector, recently joined Jeremy Maggs on Hot FM to discuss the legal, clinical, and commercial risks associated with compounded GLP-1 drugs.
Compounded GLP-1 medicines under sustained scrutiny in South Africa as SAHPRA and SAPC take enforcement action
South Africa’s regulatory stance on compounded Glucagon-like peptide 1 (GLP-1) medicines has moved from warning signals to visible enforcement. On 23 May 2026, the South African Health Products Regulatory Authority (SAHPRA), together with the South African Pharmacy Council (SAPC), announced intensified enforcement action against the unlawful manufacturing and distribution of unregistered GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) medicines containing semaglutide, tirzepatide or a combination of both, promoted for weight loss.